Elevated neutrophil‐to‐lymphocyte ratio predicts poor outcome in patients with advanced non‐small‐cell lung cancer receiving first‐line gefitinib or erlotinib treatment

Aim Elevated neutrophil‐to‐lymphocyte ratio (NLR) has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor (EGFR)‐mutated advanced non‐small‐cell lung cancer (NSCLC) patients treated with fi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Asia-Pacific journal of clinical oncology 2017-10, Vol.13 (5), p.e189-e194
Hauptverfasser: Lin, Gui‐Nan, Peng, Jie‐Wen, Liu, Pan‐Pan, Liu, Dong‐Ying, Xiao, Jian‐jun, Chen, Xiao‐Qin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e194
container_issue 5
container_start_page e189
container_title Asia-Pacific journal of clinical oncology
container_volume 13
creator Lin, Gui‐Nan
Peng, Jie‐Wen
Liu, Pan‐Pan
Liu, Dong‐Ying
Xiao, Jian‐jun
Chen, Xiao‐Qin
description Aim Elevated neutrophil‐to‐lymphocyte ratio (NLR) has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor (EGFR)‐mutated advanced non‐small‐cell lung cancer (NSCLC) patients treated with first‐line EGFR tyrosine kinase inhibitors (TKIs) is not fully addressed. Methods 81 metastatic NSCLC patients harboring EGFR mutation treated with first‐line EGFR TKIs were retrospectively included. The associations between baseline clinical characteristics, including NLR, and tumor response, progression and survival were investigated. Results Elevated NLR (≥3.5) was observed in 33 of 81 patients. The progression‐free and overall survival of the patients with increased NLR was significantly worse than that of the patients with decreased NLR (8.20 vs 10.60 months, P 
doi_str_mv 10.1111/ajco.12273
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826611768</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1957021013</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3573-f3bffedeb49a0bf248f17a3a0de5fd8ce43803d5cca2627f5242c00c1ae2869f3</originalsourceid><addsrcrecordid>eNp9kUluFDEUhi0EIgNsOACyxAZF6uChXMMyaoVJkbKBteVyPafdctmF7eqodxyBs3AkToKLClmwwAtP79P3bP0IvaLkkpbxTu11uKSMNfwJOqVNxTeNqPnTx70QJ-gspT0hvGMdfY5OmOCiYy05RT-vHRxUhgF7mHMM0866X99_5FAmdxynXdDHDDiqbAOeIgxW54SnECIOc9ZhBGw9nkoZfCnc27zDajgorxdl8EWTRuUWpwbnsJv9HdZLOeIIGuzBlgtjY8pLR-sB34Gx2Xrb49IEogvrIUdQeSxdXqBnRrkELx_Wc_T1_fWX7cfNze2HT9urm43mouEbw3tjYIC-6hTpDataQxvFFRlAmKHVUPGW8EForVjNGiNYxTQhmipgbd0Zfo7ert4phm8zpCxHm5ZPKA9hTpK2rK4pbeq2oG_-Qfdhjr68TtJONIRRQnmhLlZKx5BSBCOnaEcVj5ISuSQplyTlnyQL_PpBOfcjDI_o3-gKQFfg3jo4_kclrz5vb1fpb4oRs0c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1957021013</pqid></control><display><type>article</type><title>Elevated neutrophil‐to‐lymphocyte ratio predicts poor outcome in patients with advanced non‐small‐cell lung cancer receiving first‐line gefitinib or erlotinib treatment</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Lin, Gui‐Nan ; Peng, Jie‐Wen ; Liu, Pan‐Pan ; Liu, Dong‐Ying ; Xiao, Jian‐jun ; Chen, Xiao‐Qin</creator><creatorcontrib>Lin, Gui‐Nan ; Peng, Jie‐Wen ; Liu, Pan‐Pan ; Liu, Dong‐Ying ; Xiao, Jian‐jun ; Chen, Xiao‐Qin</creatorcontrib><description>Aim Elevated neutrophil‐to‐lymphocyte ratio (NLR) has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor (EGFR)‐mutated advanced non‐small‐cell lung cancer (NSCLC) patients treated with first‐line EGFR tyrosine kinase inhibitors (TKIs) is not fully addressed. Methods 81 metastatic NSCLC patients harboring EGFR mutation treated with first‐line EGFR TKIs were retrospectively included. The associations between baseline clinical characteristics, including NLR, and tumor response, progression and survival were investigated. Results Elevated NLR (≥3.5) was observed in 33 of 81 patients. The progression‐free and overall survival of the patients with increased NLR was significantly worse than that of the patients with decreased NLR (8.20 vs 10.60 months, P &lt; 0.001 and 17.20 vs 23.20 months, P &lt; 0.001, respectively). Elevated NLR was confirmed to be an independent prognostic factor for worse progression‐free and overall survival in Cox multivariate analysis. Conclusion Elevated NLR is likely to be associated with poor outcome in EGFR‐mutated advanced NSCLC patients treated with first‐line EGFR TKIs.</description><identifier>ISSN: 1743-7555</identifier><identifier>EISSN: 1743-7563</identifier><identifier>DOI: 10.1111/ajco.12273</identifier><identifier>PMID: 25359280</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Aged ; Carcinoma, Non-Small-Cell Lung - blood ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - pathology ; Epidermal growth factor ; epidermal growth factor receptor ; Epidermal growth factor receptors ; Erlotinib Hydrochloride - adverse effects ; Erlotinib Hydrochloride - therapeutic use ; Female ; Gefitinib ; Humans ; Lung cancer ; Lung Neoplasms - blood ; Lung Neoplasms - drug therapy ; Lung Neoplasms - pathology ; Lymphocytes - pathology ; Male ; Medical prognosis ; Metastases ; Multivariate analysis ; Neutrophils ; Neutrophils - pathology ; neutrophil‐to‐lymphocyte ratio ; Non-small cell lung carcinoma ; non‐small‐cell lung cancer ; Patients ; Predictive Value of Tests ; Prognosis ; Protein Kinase Inhibitors - adverse effects ; Protein Kinase Inhibitors - therapeutic use ; Protein-tyrosine kinase ; Quinazolines - adverse effects ; Quinazolines - therapeutic use ; Survival Analysis ; Treatment Outcome</subject><ispartof>Asia-Pacific journal of clinical oncology, 2017-10, Vol.13 (5), p.e189-e194</ispartof><rights>2014 Wiley Publishing Asia Pty Ltd</rights><rights>2014 Wiley Publishing Asia Pty Ltd.</rights><rights>Copyright © 2017 John Wiley &amp; Sons Australia, Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3573-f3bffedeb49a0bf248f17a3a0de5fd8ce43803d5cca2627f5242c00c1ae2869f3</citedby><cites>FETCH-LOGICAL-c3573-f3bffedeb49a0bf248f17a3a0de5fd8ce43803d5cca2627f5242c00c1ae2869f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fajco.12273$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fajco.12273$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25359280$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Gui‐Nan</creatorcontrib><creatorcontrib>Peng, Jie‐Wen</creatorcontrib><creatorcontrib>Liu, Pan‐Pan</creatorcontrib><creatorcontrib>Liu, Dong‐Ying</creatorcontrib><creatorcontrib>Xiao, Jian‐jun</creatorcontrib><creatorcontrib>Chen, Xiao‐Qin</creatorcontrib><title>Elevated neutrophil‐to‐lymphocyte ratio predicts poor outcome in patients with advanced non‐small‐cell lung cancer receiving first‐line gefitinib or erlotinib treatment</title><title>Asia-Pacific journal of clinical oncology</title><addtitle>Asia Pac J Clin Oncol</addtitle><description>Aim Elevated neutrophil‐to‐lymphocyte ratio (NLR) has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor (EGFR)‐mutated advanced non‐small‐cell lung cancer (NSCLC) patients treated with first‐line EGFR tyrosine kinase inhibitors (TKIs) is not fully addressed. Methods 81 metastatic NSCLC patients harboring EGFR mutation treated with first‐line EGFR TKIs were retrospectively included. The associations between baseline clinical characteristics, including NLR, and tumor response, progression and survival were investigated. Results Elevated NLR (≥3.5) was observed in 33 of 81 patients. The progression‐free and overall survival of the patients with increased NLR was significantly worse than that of the patients with decreased NLR (8.20 vs 10.60 months, P &lt; 0.001 and 17.20 vs 23.20 months, P &lt; 0.001, respectively). Elevated NLR was confirmed to be an independent prognostic factor for worse progression‐free and overall survival in Cox multivariate analysis. Conclusion Elevated NLR is likely to be associated with poor outcome in EGFR‐mutated advanced NSCLC patients treated with first‐line EGFR TKIs.</description><subject>Aged</subject><subject>Carcinoma, Non-Small-Cell Lung - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Epidermal growth factor</subject><subject>epidermal growth factor receptor</subject><subject>Epidermal growth factor receptors</subject><subject>Erlotinib Hydrochloride - adverse effects</subject><subject>Erlotinib Hydrochloride - therapeutic use</subject><subject>Female</subject><subject>Gefitinib</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - blood</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - pathology</subject><subject>Lymphocytes - pathology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Multivariate analysis</subject><subject>Neutrophils</subject><subject>Neutrophils - pathology</subject><subject>neutrophil‐to‐lymphocyte ratio</subject><subject>Non-small cell lung carcinoma</subject><subject>non‐small‐cell lung cancer</subject><subject>Patients</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Protein-tyrosine kinase</subject><subject>Quinazolines - adverse effects</subject><subject>Quinazolines - therapeutic use</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>1743-7555</issn><issn>1743-7563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUluFDEUhi0EIgNsOACyxAZF6uChXMMyaoVJkbKBteVyPafdctmF7eqodxyBs3AkToKLClmwwAtP79P3bP0IvaLkkpbxTu11uKSMNfwJOqVNxTeNqPnTx70QJ-gspT0hvGMdfY5OmOCiYy05RT-vHRxUhgF7mHMM0866X99_5FAmdxynXdDHDDiqbAOeIgxW54SnECIOc9ZhBGw9nkoZfCnc27zDajgorxdl8EWTRuUWpwbnsJv9HdZLOeIIGuzBlgtjY8pLR-sB34Gx2Xrb49IEogvrIUdQeSxdXqBnRrkELx_Wc_T1_fWX7cfNze2HT9urm43mouEbw3tjYIC-6hTpDataQxvFFRlAmKHVUPGW8EForVjNGiNYxTQhmipgbd0Zfo7ert4phm8zpCxHm5ZPKA9hTpK2rK4pbeq2oG_-Qfdhjr68TtJONIRRQnmhLlZKx5BSBCOnaEcVj5ISuSQplyTlnyQL_PpBOfcjDI_o3-gKQFfg3jo4_kclrz5vb1fpb4oRs0c</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>Lin, Gui‐Nan</creator><creator>Peng, Jie‐Wen</creator><creator>Liu, Pan‐Pan</creator><creator>Liu, Dong‐Ying</creator><creator>Xiao, Jian‐jun</creator><creator>Chen, Xiao‐Qin</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>201710</creationdate><title>Elevated neutrophil‐to‐lymphocyte ratio predicts poor outcome in patients with advanced non‐small‐cell lung cancer receiving first‐line gefitinib or erlotinib treatment</title><author>Lin, Gui‐Nan ; Peng, Jie‐Wen ; Liu, Pan‐Pan ; Liu, Dong‐Ying ; Xiao, Jian‐jun ; Chen, Xiao‐Qin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3573-f3bffedeb49a0bf248f17a3a0de5fd8ce43803d5cca2627f5242c00c1ae2869f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Carcinoma, Non-Small-Cell Lung - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Epidermal growth factor</topic><topic>epidermal growth factor receptor</topic><topic>Epidermal growth factor receptors</topic><topic>Erlotinib Hydrochloride - adverse effects</topic><topic>Erlotinib Hydrochloride - therapeutic use</topic><topic>Female</topic><topic>Gefitinib</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - blood</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - pathology</topic><topic>Lymphocytes - pathology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Multivariate analysis</topic><topic>Neutrophils</topic><topic>Neutrophils - pathology</topic><topic>neutrophil‐to‐lymphocyte ratio</topic><topic>Non-small cell lung carcinoma</topic><topic>non‐small‐cell lung cancer</topic><topic>Patients</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Protein-tyrosine kinase</topic><topic>Quinazolines - adverse effects</topic><topic>Quinazolines - therapeutic use</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Gui‐Nan</creatorcontrib><creatorcontrib>Peng, Jie‐Wen</creatorcontrib><creatorcontrib>Liu, Pan‐Pan</creatorcontrib><creatorcontrib>Liu, Dong‐Ying</creatorcontrib><creatorcontrib>Xiao, Jian‐jun</creatorcontrib><creatorcontrib>Chen, Xiao‐Qin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Asia-Pacific journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Gui‐Nan</au><au>Peng, Jie‐Wen</au><au>Liu, Pan‐Pan</au><au>Liu, Dong‐Ying</au><au>Xiao, Jian‐jun</au><au>Chen, Xiao‐Qin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elevated neutrophil‐to‐lymphocyte ratio predicts poor outcome in patients with advanced non‐small‐cell lung cancer receiving first‐line gefitinib or erlotinib treatment</atitle><jtitle>Asia-Pacific journal of clinical oncology</jtitle><addtitle>Asia Pac J Clin Oncol</addtitle><date>2017-10</date><risdate>2017</risdate><volume>13</volume><issue>5</issue><spage>e189</spage><epage>e194</epage><pages>e189-e194</pages><issn>1743-7555</issn><eissn>1743-7563</eissn><abstract>Aim Elevated neutrophil‐to‐lymphocyte ratio (NLR) has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor (EGFR)‐mutated advanced non‐small‐cell lung cancer (NSCLC) patients treated with first‐line EGFR tyrosine kinase inhibitors (TKIs) is not fully addressed. Methods 81 metastatic NSCLC patients harboring EGFR mutation treated with first‐line EGFR TKIs were retrospectively included. The associations between baseline clinical characteristics, including NLR, and tumor response, progression and survival were investigated. Results Elevated NLR (≥3.5) was observed in 33 of 81 patients. The progression‐free and overall survival of the patients with increased NLR was significantly worse than that of the patients with decreased NLR (8.20 vs 10.60 months, P &lt; 0.001 and 17.20 vs 23.20 months, P &lt; 0.001, respectively). Elevated NLR was confirmed to be an independent prognostic factor for worse progression‐free and overall survival in Cox multivariate analysis. Conclusion Elevated NLR is likely to be associated with poor outcome in EGFR‐mutated advanced NSCLC patients treated with first‐line EGFR TKIs.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>25359280</pmid><doi>10.1111/ajco.12273</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1743-7555
ispartof Asia-Pacific journal of clinical oncology, 2017-10, Vol.13 (5), p.e189-e194
issn 1743-7555
1743-7563
language eng
recordid cdi_proquest_miscellaneous_1826611768
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Aged
Carcinoma, Non-Small-Cell Lung - blood
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - pathology
Epidermal growth factor
epidermal growth factor receptor
Epidermal growth factor receptors
Erlotinib Hydrochloride - adverse effects
Erlotinib Hydrochloride - therapeutic use
Female
Gefitinib
Humans
Lung cancer
Lung Neoplasms - blood
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Lymphocytes - pathology
Male
Medical prognosis
Metastases
Multivariate analysis
Neutrophils
Neutrophils - pathology
neutrophil‐to‐lymphocyte ratio
Non-small cell lung carcinoma
non‐small‐cell lung cancer
Patients
Predictive Value of Tests
Prognosis
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
Protein-tyrosine kinase
Quinazolines - adverse effects
Quinazolines - therapeutic use
Survival Analysis
Treatment Outcome
title Elevated neutrophil‐to‐lymphocyte ratio predicts poor outcome in patients with advanced non‐small‐cell lung cancer receiving first‐line gefitinib or erlotinib treatment
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-17T12%3A45%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elevated%20neutrophil%E2%80%90to%E2%80%90lymphocyte%20ratio%20predicts%20poor%20outcome%20in%20patients%20with%20advanced%20non%E2%80%90small%E2%80%90cell%20lung%20cancer%20receiving%20first%E2%80%90line%20gefitinib%20or%20erlotinib%20treatment&rft.jtitle=Asia-Pacific%20journal%20of%20clinical%20oncology&rft.au=Lin,%20Gui%E2%80%90Nan&rft.date=2017-10&rft.volume=13&rft.issue=5&rft.spage=e189&rft.epage=e194&rft.pages=e189-e194&rft.issn=1743-7555&rft.eissn=1743-7563&rft_id=info:doi/10.1111/ajco.12273&rft_dat=%3Cproquest_cross%3E1957021013%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1957021013&rft_id=info:pmid/25359280&rfr_iscdi=true